Chest MRI to diagnose early diaphragmatic weakness in Pompe disease.
Diaphragm
Lysosomal storage disease
MRI
Neuromuscular disease
Pompe disease
Respiratory function
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
07 01 2021
07 01 2021
Historique:
received:
05
07
2020
accepted:
27
11
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
22
6
2021
Statut:
epublish
Résumé
In Pompe disease, an inherited metabolic muscle disorder, severe diaphragmatic weakness often occurs. Enzyme replacement treatment is relatively ineffective for respiratory function, possibly because of irreversible damage to the diaphragm early in the disease course. Mildly impaired diaphragmatic function may not be recognized by spirometry, which is commonly used to study respiratory function. In this cross-sectional study, we aimed to identify early signs of diaphragmatic weakness in Pompe patients using chest MRI. Pompe patients covering the spectrum of disease severity, and sex and age matched healthy controls were prospectively included and studied using spirometry-controlled sagittal MR images of both mid-hemidiaphragms during forced inspiration. The motions of the diaphragm and thoracic wall were evaluated by measuring thoracic cranial-caudal and anterior-posterior distance ratios between inspiration and expiration. The diaphragm shape was evaluated by measuring the height of the diaphragm curvature. We used multiple linear regression analysis to compare different groups. We included 22 Pompe patients with decreased spirometry results (forced vital capacity in supine position < 80% predicted); 13 Pompe patients with normal spirometry results (forced vital capacity in supine position ≥ 80% predicted) and 18 healthy controls. The mean cranial-caudal ratio was only 1.32 in patients with decreased spirometry results, 1.60 in patients with normal spirometry results and 1.72 in healthy controls (p < 0.001). Anterior-posterior ratios showed no significant differences. The mean height ratios of the diaphragm curvature were 1.41 in patients with decreased spirometry results, 1.08 in patients with normal spirometry results and 0.82 in healthy controls (p = 0.001), indicating an increased curvature of the diaphragm during inspiration in Pompe patients. Even in early-stage Pompe disease, when spirometry results are still within normal range, the motion of the diaphragm is already reduced and the shape is more curved during inspiration. MRI can be used to detect early signs of diaphragmatic weakness in patients with Pompe disease, which might help to select patients for early intervention to prevent possible irreversible damage to the diaphragm.
Sections du résumé
BACKGROUND
In Pompe disease, an inherited metabolic muscle disorder, severe diaphragmatic weakness often occurs. Enzyme replacement treatment is relatively ineffective for respiratory function, possibly because of irreversible damage to the diaphragm early in the disease course. Mildly impaired diaphragmatic function may not be recognized by spirometry, which is commonly used to study respiratory function. In this cross-sectional study, we aimed to identify early signs of diaphragmatic weakness in Pompe patients using chest MRI.
METHODS
Pompe patients covering the spectrum of disease severity, and sex and age matched healthy controls were prospectively included and studied using spirometry-controlled sagittal MR images of both mid-hemidiaphragms during forced inspiration. The motions of the diaphragm and thoracic wall were evaluated by measuring thoracic cranial-caudal and anterior-posterior distance ratios between inspiration and expiration. The diaphragm shape was evaluated by measuring the height of the diaphragm curvature. We used multiple linear regression analysis to compare different groups.
RESULTS
We included 22 Pompe patients with decreased spirometry results (forced vital capacity in supine position < 80% predicted); 13 Pompe patients with normal spirometry results (forced vital capacity in supine position ≥ 80% predicted) and 18 healthy controls. The mean cranial-caudal ratio was only 1.32 in patients with decreased spirometry results, 1.60 in patients with normal spirometry results and 1.72 in healthy controls (p < 0.001). Anterior-posterior ratios showed no significant differences. The mean height ratios of the diaphragm curvature were 1.41 in patients with decreased spirometry results, 1.08 in patients with normal spirometry results and 0.82 in healthy controls (p = 0.001), indicating an increased curvature of the diaphragm during inspiration in Pompe patients.
CONCLUSIONS
Even in early-stage Pompe disease, when spirometry results are still within normal range, the motion of the diaphragm is already reduced and the shape is more curved during inspiration. MRI can be used to detect early signs of diaphragmatic weakness in patients with Pompe disease, which might help to select patients for early intervention to prevent possible irreversible damage to the diaphragm.
Identifiants
pubmed: 33413525
doi: 10.1186/s13023-020-01627-x
pii: 10.1186/s13023-020-01627-x
pmc: PMC7789462
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21Références
Neuromuscul Disord. 2018 Mar;28(3):246-256
pubmed: 29398294
Mol Genet Metab. 2013 Nov;110(3):290-6
pubmed: 23916420
Neuromuscul Disord. 2016 Feb;26(2):136-45
pubmed: 26794303
Thorax. 2004 Sep;59(9):808-17
pubmed: 15333861
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
J Neurol. 2012 May;259(5):952-8
pubmed: 22081099
N Engl J Med. 2010 Apr 15;362(15):1396-406
pubmed: 20393176
Rev Port Pneumol (2006). 2017 Jul - Aug;23(4):208-215
pubmed: 28499810
Pediatrics. 2003 Aug;112(2):332-40
pubmed: 12897283
Neurology. 2019 Nov 5;93(19):e1756-e1767
pubmed: 31619483
BMC Pulm Med. 2015 May 06;15:54
pubmed: 25943437
Orphanet J Rare Dis. 2012 Nov 12;7:88
pubmed: 23147228
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
N Engl J Med. 2012 Mar 8;366(10):932-42
pubmed: 22397655
Eur J Neurol. 2017 Jun;24(6):768-e31
pubmed: 28477382
Thorax. 1984 Jul;39(7):535-8
pubmed: 6463933
J Inherit Metab Dis. 2013 Sep;36(5):787-94
pubmed: 23053471
Neurol Sci. 2020 Aug;41(8):2175-2184
pubmed: 32162165
PLoS One. 2016 Jul 08;11(7):e0158912
pubmed: 27391236
Am J Respir Crit Care Med. 2002 Aug 15;166(4):518-624
pubmed: 12186831
Mol Genet Metab. 2011 Sep-Oct;104(1-2):129-36
pubmed: 21763167
Mol Genet Metab. 2016 Apr;117(4):413-8
pubmed: 26873529
Neuromuscul Disord. 2015 Nov;25(11):852-8
pubmed: 26410244
J Neurol. 2019 Nov;266(11):2752-2763
pubmed: 31350642
Arch Phys Med Rehabil. 2001 Jan;82(1):123-8
pubmed: 11239298
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Lancet. 2008 Oct 11;372(9646):1342-53
pubmed: 18929906
Neurology. 2017 Dec 5;89(23):2365-2373
pubmed: 29117951
Eur Respir J. 1991 May;4(5):587-601
pubmed: 1936230
Acta Myol. 2007 Jul;26(1):45-8
pubmed: 17915569
Neuromuscul Disord. 2016 Aug;26(8):481-9
pubmed: 27297666
Orphanet J Rare Dis. 2019 Mar 4;14(1):62
pubmed: 30832705